Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GPCR antagonist (Hope Medicine)
- Development stage
- Preclinical
- Lead developer
- HopeMed
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
GPCR antagonist (Program 1) is an investigational drug candidate being developed by Hope Medicine for the treatment of myocardial infarction. The drug acts as an antagonist of a G protein-coupled receptor (GPCR), a large family of cell surface receptors involved in various physiological and pathological processes, including cardiovascular signaling. By targeting a specific GPCR, the program aims to modulate pathways that contribute to cardiac injury or adverse remodeling following an ischemic event such as a heart attack. Currently in the early stages of development (exploratory or lead optimization), this program represents part of Hope Medicine's focus on leveraging GPCR biology to address unmet needs in cardiovascular and metabolic diseases.
- Other names
- GPCR antagonist (Program 1)
Beyond the preview
Go deeper on GPCR antagonist (Hope Medicine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GPCR antagonist (Hope Medicine).